HTG Molecular Diagnostics, Inc. Net Change in Cash
HTG Molecular Diagnostics, Inc. reported Net Change in Cash of -$9.21 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2023-05-11
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$9.21M, a 283.76% decline year-over-year.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was $5.01M.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was -$620.13K, a 122.28% decline year-over-year.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $2.78M.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $2.61M.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was -$12.80M, a 211.21% decline from fiscal 2020.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $11.51M.
- HTG Molecular Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$812.85K, a 146.87% decline from fiscal 2018.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$9.21M 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $2.61M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | -$6.39M 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | -$3.84M 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $5.01M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$12.80M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | -$12.17M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$8.82M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$620.13K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $11.51M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $7.99M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $10.12M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $2.78M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$812.85K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $26.41M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | $3.38M 10-Q · filed 2020-08-11 | |||
| 2019-03-31 | -$1.46M 10-Q · filed 2020-05-13 | |||
| 2018-12-31 | $1.73M 10-K · filed 2020-03-25 | |||
| 2018-09-30 | -$534.35K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$4.19M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $10.56M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $2.46M 10-K · filed 2019-03-07 | |||
| 2017-09-30 | $1.54M 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $5.89M 10-Q · filed 2018-08-09 |